Hepatoprotective effect of magnesium isoglycyrrhizinate injection on patients undergoing transcatheter arterial chemoembolization

Objective:To observe the hepatoprotective effect of Magnesium Isoglycyrrhizinate Injection on patients undergoing transcatheter arterial chemoembolization( TACE). Methods:A total of 46 patients with primary hepatocellular carcinoma( PHC) were randomized to trial and control group. The control group received supporting treatment alone from the first TACE day,while the trial group received Magnesium Isoglycyrrhizinate Injection 150mg / d in combination with supporting treatment for10 consecutive days.Results:The symptoms of two groups were significantly improved( P 0.05),but the improving days had significant differences( P 0.05).The trial group showed no significant differences in parameters of liver function before and after receiving TACE On days 3 and 7 after the completion of TACE,the total bilirubin level in control group was significantly higher than in trial group( P 0. 01),but slightly reduced on days 14, yet it was still higher than in the trial group( P 0.05) On days 3 and 7 after the completion of TACE,the ALT and AST levels in the control group( P 0. 01) were significantly higher than in the trial group( P 0.01),but reduced to the normal level on days 14; the ALB level began to decrease significantly from day 7 after the completion of TACE( P 0.05),but rebounded slightly on day 14, yet it failed to return to the normal level( P 0. 05).Conclusion:Magnesium Isoglycyrrhizinate Injection could prevent hepatocellular damage and protect liver function and enhance patients' tolerance to TACE.